Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 14/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680939 | 0.85 | CETP (0.46) | CETP | |
| SCHEMBL680940 | 0.85 | CETP (0.46) | CETP | |
| SCHEMBL1587966 | 0.76 | CETP (0.47) | CETPKDM4EPOLBNPSR1LMNA | |
| SCHEMBL1588389 | 0.75 | CETP (0.51) | CETPRAF1BRAFKDM4EPOLB | |
| SCHEMBL1587594 | 0.75 | CETP (0.49) | CETPRAF1BRAFLMNASMN1; SMN2 | |
| SCHEMBL17414297 | 0.75 | CETP (0.41) | CETP | |
| SCHEMBL13236903 | 0.75 | CETP (0.46) | CETPLCK | |
| SCHEMBL1587732 | 0.74 | CETP (0.45) | CETPRAF1BRAFKDM4EPOLB | |
| SCHEMBL685132 | 0.74 | CETP (0.38) | CETP | |
| SCHEMBL15702951 | 0.74 | CETP (0.39) | CETPRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | KOWA COMPANY, LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | ACSL6, ACSL3, ACSL1 | CETP 274/4885RAF1 1963/4885BRAF 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.